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Abstract
Mitochondrial disease is hugely diverse with respect to associated clinical presenta-
tions and underlying genetic causes, with pathogenic variants in over 300 disease
genes currently described. Approximately half of these have been discovered in the
last decade due to the increasingly widespread application of next generation
sequencing technologies, in particular unbiased, whole exome—and latterly, whole
genome sequencing. These technologies allow more genetic data to be collected from
patients with mitochondrial disorders, continually improving the diagnostic success
rate in a clinical setting. Despite these significant advances, some patients still remain
without a definitive genetic diagnosis. Large datasets containing many variants of
unknown significance have become a major challenge with next generation sequenc-
ing strategies and these require significant functional validation to confirm pathoge-
nicity. This interface between diagnostics and research is critical in continuing to
expand the list of known pathogenic variants and concomitantly enhance our knowl-
edge of mitochondrial biology. The increasing use of whole exome sequencing,
whole genome sequencing and other “omics” techniques such as transcriptomics and
proteomics will generate even more data and allow further interrogation and valida-
tion of genetic causes, including those outside of coding regions. This will improve
diagnostic yields still further and emphasizes the integral role that functional assess-
ment of variant causality plays in this process—the overarching focus of this review.
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1 | INTRODUCTION
1.1 | Mitochondrial disease overview
Mitochondrial disorders are the most common group of
inborn errors of metabolism with an estimated minimum
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4.7 per 100 000 in children.2 “Mitochondrial disease” is a
collective term for many different clinical disorders united
by the common features of failure of mitochondrial function
and aberrant energy metabolism.3 Mitochondrial disorders
can present at any age and result from pathogenic variants in
either the nuclear genome (nDNA) or mitochondrial genome
(mtDNA). Due to this dual genetic control of mitochondrial
function, these disorders can be inherited with any inheri-
tance pattern: sporadic, maternal, autosomal dominant, auto-
somal recessive or X-linked.
Mitochondria are present in all nucleated cell types and
therefore, mitochondrial disease may affect any organ or tis-
sue in the body. Some patients have an organ specific
disease—“pure” myopathy, cardiomyopathy or optic neu-
ropathy, while others have multisystem involvement at pre-
sentation or acquire this during the course of their
progressive disease. While there may be some diagnostic,
and potentially prognostic, utility in categorising the myriad
clinical features as particular syndromes e.g. MELAS (Mito-
chondrial encephalomyopathy, lactic acidosis, and stroke-
like episodes); MERRF (Myoclonic epilepsy with ragged
red fibres); LHON (Leber hereditary optic neuropathy);
NARP (Neuropathy, ataxia, and retinitis pigmentosa); Leigh
Syndrome and Pearson Syndrome, the reality is that many
patients do not fit easily into this syndromic classification.
A further complication is that genotype-phenotype correla-
tions in mitochondrial disease are often poor, even within
these defined syndromes. For example, Leigh syndrome,
which presents as a progressive neurodegenerative disorder
in childhood, exhibits marked genetic variability and is asso-
ciated with pathogenic variants in more than 75 different
mtDNA or nDNA genes.4,5 Conversely, a single genotype
can present with a range of phenotypes; the most common
heteroplasmic pathogenic mtDNA variant, m.3243A > G,
can present with a classic MELAS phenotype, but also with
MIDD (Maternally-inherited diabetes and deafness), sensori-
neural hearing loss, myopathy, cardiomyopathy, seizures,
migraine, ataxia, cognitive impairment, bowel dysmotility,
short stature, diabetes, external ophthalmoplegia or Leigh
syndrome and 9% of individuals are asymptomatic.6 The
vast clinical and genetic heterogeneity of mitochondrial dis-
ease coupled with poor genotype-phenotype correlations
makes the genetic diagnosis of patients a challenging task.
1.2 | Mitochondrial function and genetics
Mitochondria are dynamic organelles that are responsible for
the generation of adenosine triphosphate (ATP) via oxidative
phosphorylation (OXPHOS); approximately 90% of the
energy requirement of the cell is met through hydrolysis of
ATP produced this way.7 However, mitochondria are also
involved in many other processes including, but not limited
to, iron sulfur cluster formation,8 the citric acid cycle,9 regu-
lation of apoptosis10 and calcium homeostasis in conjunction
with the endoplasmic reticulum.11
Human mtDNA is a closed-circular molecule of
16 569 bp and encodes 37 genes; 13 polypeptides, 22 trans-
fer RNAs (tRNAs) and 2 ribosomal RNAs (rRNAs).12 The
mitochondrial genome is exclusively maternally-inherited
and is present in multiple copies within cells. Cells can be
homoplasmic, where all mtDNA molecules are identical, or
heteroplasmic, where two (or more) variant populations of
mtDNA exist within one cell. Heteroplasmy levels are a fac-
tor in determining the aforementioned clinical heterogeneity
in patients harboring the common pathogenic m.3243A > G
variant.13 However, heteroplasmy does not fully explain the
phenotypic variability with sex14 and heritable nuclear fac-
tors15 likely to play a role.
All 13 mtDNA-encoded proteins are essential hydropho-
bic components of the OXPHOS system located in the inner
mitochondrial membrane (IMM). The OXPHOS system
comprises five multi-subunit complexes and two electron
carriers (ubiquinone and cytochrome c). Complexes I-IV
and the electron carriers constitute the electron transport
chain, which establishes an electrochemical gradient across
the IMM that is then dissipated via complex V (the F1FO
ATP synthase) to synthesize ATP. Individual OXPHOS
complexes can also combine into larger complexes; the crys-
tal structures of some of these supercomplexes, including the
mammalian respirasome, have recently been elucidated.16,17
In addition to the 13 polypeptides encoded by mtDNA,
more than 60 further nuclear-encoded respiratory chain pro-
teins are translated in the cytosol and imported into mito-
chondria prior to incorporation into the OXPHOS
complexes. Indeed, the nuclear genome accounts for 99% of
the mitochondrial proteome which is estimated to comprise
1158 total mitochondrial proteins.18 A large proportion of
these proteins have important roles in OXPHOS, either
directly as respiratory complex subunits, cofactors, assembly
factors and substrate-generating upstream pathways, or more
indirectly, for example, factors involved in the expression of
mtDNA-encoded genes. Mitochondrial gene expression
requires proteins involved in mtDNA maintenance, tran-
scription, RNA processing/maturation, translation and post-
translational insertion into the IMM. Furthermore, all of
these proteins need to be correctly targeted and imported
into the mitochondria. Thus, any defects in mitochondrial
protein import or the structure of the mitochondria, caused
by aberrant cristae formation or abnormal membrane lipid
composition, as well as factors affecting mitochondrial fis-
sion and fusion can also negatively impact the OXPHOS
system. The genetic heterogeneity of mitochondrial disor-
ders is a consequence of this wide range of proteins that
impact OXPHOS function. Over 300 mitochondrial disease-
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mtDNA pathogenic variants: 36/37 genes
OXPHOS 
subunits
(CI) MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND4L, MT-ND5, MT-ND6; (CIII) MT-CYB; (CIV) MT-CO1, MT-CO2, 
MT-CO3; (CV) MT-ATP6, MT-ATP8
Ribosomal RNA MT-RNR1
Transfer RNA MT-TA, MT-TC, MT-TD, MT-TE, MT-TF, MT-TG, MT-TH, MT-TI, MT-TK, MT-TL1, MT-TL2, MT-TM, MT-TN, MT-TP, MT-TQ, MT-TR, MT-TS1, MT-TS2, MT-TT, MT-TV, MT-TW, MT-TY
Nuclear pathogenic variants: 295 genes
OXPHOS 
subunits
Complex I
NDUFA1, NDUFA2, NDUFA6, 
NDUFA9, NDUFA10, NDUFA11, 
NDUFA12, NDUFA13
NDUFB3, NDUFB8, NDUFB9, 
NDUFB10, NDUFB11
NDUFS1, NDUFS2, NDUFS3, 
NDUFS4, NDUFS6, NDUFS7, 
NDUFS8
NDUFV1, NDUFV2
Complex II
SDHA, SDHB, 
SDHD
Complex III
CYC1, 
UQCRB, 
UQCRQ, 
UQCRC2
Complex IV
COX4I1, 
COX4I2, COX5A, 
COX6A1, COX6B1,  
COX7B, COX8A, 
NDUFA4
Complex V
ATP5F1A, 
ATP5F1D, 
ATP5F1E
OXPHOS 
assembly 
factors
ACAD9, FOXRED1, NDUFAF1, 
NDUFAF2, NDUFAF3, 
NDUFAF4, NDUFAF5, 
NDUFAF6, NDUFAF8, NUBPL
TIMMDC1, TMEM126B
SDHAF1 BCS1L, 
LYRM7, 
TTC19, 
UQCC2, 
UQCC3
CEP89, COX14, 
COX20, COA3,
COA5, COA7, 
PET100, PET117, 
SURF1
ATPAF2, 
TMEM70
Protein import & 
processing
AFG3L2, AIFM1, CLPB, CLPP, DNAJC19, GFER, HSPD1, HTRA2, LONP1, MIPEP, PITRM1, PMPCA, PMPCB, 
SACS, SPG7, TIMM22, TIMM50, TIMM8A, XPNPEP3, YME1L
mtDNA 
replication & 
maintenance
ABAT, DGUOK, DNA2, MGME1, MPV17, POLG, POLG2, RNASEH1, RRM2B, SAMHD1, SLC25A4, SSBP1, 
SUCLA2, SUCLG1, TFAM, TK2, TOP3A, TWNK, TYMP
RNA maturation/
modification
ELAC2, ERAL1, FASTKD2, GTPBP3, HSD17B10, LRPPRC, MRM2, MTFMT, MTO1, MTPAP, NSUN3, PNPT1, 
PUS1, TRIT1, TRMT10C, TRMT5, TRMU, TRNT1
Mitochondrial 
aminoacyl tRNA 
synthetases
AARS2, CARS2, DARS2, EARS2, FARS2, GARS, GATB, GATC, HARS2, IARS2, KARS, LARS2, MARS2, NARS2, 
PARS2, QRSL1, RARS2, SARS2, TARS2, VARS2, WARS2, YARS2
Mitoribosome MRPS2, MRPS7, MRPS14, MRPS16, MRPS22, MRPS23, MRPS28, MRPS34, MRPL3, MRPL12, MRPL44, PTCD3
Translation C12orf65, GFM1, GFM2, RMND1, TACO1, TSFM, TUFM
Membrane 
dynamics & 
composition
AGK, CHKB, DNM1L, GDAP1, MFF, MFN2, MSTO1, NME3, OPA1, OXA1L, PGA2G6, PNPLA4, PNPLA8, QIL1, 
SERAC1, SLC25A46, STAT2, TAZ, TRAK1, VPS13C
β-oxidation ACADM, ACADS, ACADSB, ACADVL, ACAT1, CPT1A, CPT2, ETFA, ETFB, ETFDH, HADH, HADHA, HADHB, HMGCL, HMGCS2, OXCT1, SLC22A5, SLC25A20
TCA cycle ACO2, ALDH18A1, CA5A, DLAT, FH, HAAO, IDH3A, IDH3B, KYNU, MDH2, MPC1, PC, PDHA1, PDHB, PDHX, PDK3, PDP1, PPA2, SLC25A12, SLC25A13, SLC25A3
Cofactors
ABCB7, BOLA3, C19ORF12, COA6, COASY, COQ2, COQ4, COQ5, COQ6, COQ7, COQ8A, COQ8B, COQ9, 
COX10, COX15, CYCS, DLD, FDX1L, FDXR, FLAD1, FXN, GLRX5, HCCS, IBA57, ISCA1, ISCA2, ISCU, LIAS, 
LIPT1, LIPT2, LYRM4, MECR, MICU1, MICU2, NADK2, NAXE, NFS1, NFU1, PANK2, PDSS1, PDSS2, SCO1, SCO2, 
SFXN4, SLC19A2, SLC19A3, SLC25A19, SLC25A24, SLC25A26, SLC25A32, SLC25A42, SLC39A8, TPK1
Other APOPT1, ATAD3A, C1QBP, CHCHD10, D2HGDH, ECHS1, ETHE1, FBXL4, HIBCH, IARS, L2HGDH, OPA3, RTN4IP1, SLC25A1, TMEM65, TXN2
FIGURE 1 List of genes currently associated with mitochondrial disease sorted according to function. Some genes have more than one
mitochondrial function, so we have used broad categories to ensure their most appropriate assignment. Our selection criteria necessitated causative
genes have a primary or secondary impact on OXPHOS and does not include genes where variants have been described in cancer, but not a
mitochondrial disorder (eg, SDHC). Over 150 genes linked to mitochondrial disease have been discovered since the implementation of next
generation sequencing (NGS) in 2010. Today, pathogenic variants in 36/37 mitochondrial-encoded genes and 295 nuclear-encoded mitochondrial
genes have been shown to affect mitochondrial energy metabolism, highlighting the impact NGS has had in the identification of causative genes that
are associated with a wide range of mitochondrial functions
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associated genes have been described to date (Figure 1)—a
list that has grown enormously over the last decade largely
due to the advent and application of next generation
sequencing (NGS) technologies.
The impact of NGS in identifying novel disease genes can
be illustrated using examples related to mitochondrial protein
synthesis. Before the advent of widespread NGS, surprisingly
few of the genes encoding proteins involved in mitochondrial
protein synthesis were associated with disease. The first to be
described was a variant in MRPS16 encoding a subunit of the
mitoribosome.19 Only one other mitoribosomal component
(MRPS22) was associated with disease20 before NGS was
introduced, but since then pathogenic variants in MRPL3,21
MRPL44,22 MRPL12,23 MRPS7,24 MRPS23,25 MRPS34,26
MRPS2,27 MRPS14,28 MRPS2829 and MRPS3930 have been
identified in patients. All were discovered by NGS methods
with the exception of MRPL12 which was identified using
microsatellite genotyping and Sanger sequencing.23 Similarly,
prior to use of NGS, only three mitochondrial aminoacyl
tRNA synthetases were established as disease genes; the first
described was the aspartyl tRNA synthetase (DARS231)
followed by the arginyl (RARS232) and tyrosyl (YARS233)
aminoacyl tRNA synthetases. The remaining 14 mitochondrial
tRNA synthetases (AARS2, CARS2, EARS2, FARS2, HARS2,
IARS2, LARS2, MARS2, NARS2, PARS2, SARS2, TARS2,
VARS2 and WARS2) plus GARS and KARS, which encode
synthetases used in both the cytosol and the mitochondrion,
were all identified as disease genes by NGS, with the last one
to be found being WARS2.34-36 Mitochondria do not contain a
glutaminyl tRNA synthetase, instead tRNAGln is first charged
with Glu by EARS2 before a transamidation reaction converts
the Glu-mt-tRNAGln to Gln-mt-tRNAGln. This reaction is cat-
alyzed by GatCAB, the glutamyl-tRNAGln amidotransferase
protein complex, which consists of three proteins encoded
by QRSL1, GATB and GATC respectively. Until recently,
only variants in QRSL1 were associated with disease,25 but
the first pathogenic variants in GATB and GATC have now
been identified in patients.37 This completes the list of genes
involved in mitochondrial tRNA aminoacylation associated
with mitochondrial disorders.
This clearly demonstrates the impact of next generation
sequencing in terms of expanding the spectrum of genes
associated with disease; advances in sequencing technology
will facilitate further gene discovery and this list is likely to
continue expanding for some time yet.38
2 | GENETIC DIAGNOSIS OF
MITOCHONDRIAL DISORDERS:
SEQUENCING STRATEGIES
Traditionally, initial suspicion of mitochondrial disease
relies upon varied clinical observations, metabolic
changes, such as increased plasma or cerebrospinal fluid
(CSF) lactate or urinary 3-methylglutaconic acid,39 and
neuroimaging.40 All of these can be indicators of a mito-
chondrial etiology, but are not in themselves unique to
mitochondrial patients; the complexity of these disorders
means that a clear diagnostic algorithm can be difficult to
implement. This raises a number of questions concerning
diagnosis in an era when NGS is so prevalent. When to
perform a muscle biopsy and integrate functional testing?
Which sequencing strategy should be used? Is a “multi-
omics” approach the future of mitochondrial diagnostics?
Which experiments are necessary to affirm pathogenicity
of novel gene variants or candidate disease genes? Here,
we will dissect the importance and application of NGS
technologies and discuss the functional validation of novel
disease genes. Figure 2 outlines an overview of the various
stages and techniques involved in the genetic diagnosis of
mitochondrial disorders and will be expanded upon
throughout the remainder of this review.
Historically, genetic diagnosis of mitochondrial disease
was achieved through candidate gene studies guided by
histochemical and biochemical phenotyping of patient tis-
sue, usually collected from a skeletal muscle biopsy. This
has been described as a “biopsy first” or “from function to
gene” approach.41 Only in cases with very clear syndromic
presentations would a genetic test be carried out prior to a
muscle biopsy, for example, a child presenting with
MELAS would be tested for the common m.3243A > G
MT-TL1 pathogenic variant. The advent of NGS has since
revolutionized the diagnosis of many rare genetic disor-
ders, especially heterogeneous disorders such as mitochon-
drial disease. Over the past decade a number of NGS
approaches have been successful including whole mtDNA
sequencing,42 targeted gene panels (eg, complex I),43
targeted exome sequencing (“MitoExome”),44,45 whole
exome sequencing (WES),25,46-48 whole genome sequenc-
ing (WGS)49 and RNA-Seq.50 We will further discuss the
impact and merits of each strategy below.
2.1 | Whole mtDNA sequencing
Using NGS for whole mtDNA sequencing allows any
mtDNA variant to be identified and gives accurate assess-
ment of heteroplasmy levels.42 It remains common practice
in many mitochondrial diagnostic centers to first sequence
the mtDNA to exclude mitochondrial variants before per-
forming WES or WGS. In adult-onset cases, a mtDNA etiol-
ogy is far more common, so whole mtDNA sequencing
remains a more pragmatic option than going directly to
WES/WGS. It is important to remember that many patho-
genic mtDNA variants are restricted to clinically-affected tis-
sues such as skeletal muscle.51
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Confirmation of variant pathogenicity and involvement in impaired mitochondrial OXPHOS metabolism 
• Enzyme histochemistry and spectrophotometric respiratory 
chain enzyme activity assays
• Quadruple-label immunofluorescence
• Steady-state levels of protein encoded by variant gene 
(SDS-PAGE)
• OXPHOS protein steady-state levels (SDS-PAGE) and 
assembly (BN-PAGE)
• RNA/splicing studies
• Spectrophotometric respiratory chain enzyme activity 
assays
• Steady-state levels of protein encoded by variant gene 
(SDS-PAGE)
• OXPHOS protein steady-state levels (SDS-PAGE) and 
assembly (BN-PAGE)
• Respiration studies and glucose/galactose growth assay
• RNA/splicing studies
Tissue (e.g. skeletal muscle biopsy) Cells (e.g. primary fibroblast culture)
Patient with suspected 
mitochondrial disease
Trio WES/WGS
• Screen common variants if recognised clinical 
syndrome (e.g. m.3243A>G in MELAS)
• Full mtDNA sequencing
• Muscle biopsy if clinically-indicated (e.g. adult CPEO 
phenotypes to screen for mtDNA rearrangements)
If no variants identified
Additional investigations to assess disease mechanisms associated with mitochondrial disease
Known disease gene
Known variant
Novel disease gene
Known function
Novel disease gene
Unknown function
No Clear Candidate 
Variants
Known disease gene
Novel variant
• Segregation
• Phenotype-genotype 
correlation
• Phenotype-genotype 
correlation
• Similar biochemical 
phenotype to previous 
reported mutations
• Show expected 
molecular phenotype 
based on function
• GeneMatcher to 
identify other patients
• Rescue experiments
• Extensive assessment 
of mitochondrial function
• GeneMatcher to identify 
other patients
• Model systems
• Rescue experiments
• Filtering strategies
• Further sequencing 
e.g. WGS if only WES 
• RNA-Seq
• Other ‘omics’ 
approaches
Bioinformatic filtering and 
variant prioritisation
Protein/RNA Analyses
• Complexome profiling
• Protein-protein interactions 
(Co-IP, Bio-ID, TAP, Y2H)
• Protein-RNA (CLIP) 
• RNA-RNA (EMSA)
• Transcriptomics
Imaging
• Electron microscopy (TEM, 
SBF-SEM)
• Confocal microscopy
(iSim, spinning disc)
• STED microscopy
• FRET
Cell-lines and Models
• CRISPR-Cas9
• iPSC generation and 
differentiation
• Model systems (yeast, 
drosophila, zebrafish, 
mouse)
Transcription & 
mtDNA Maintenance
• Nucleoid morphology
• mtDNA and mRNA 
expression levels 
(Southern/Northern blots)
• In vitro transcription assays
Translation
• [35S] mitochondrial protein 
synthesis assay
• Sucrose gradient: 
mitoribosome assembly
• tRNA aminoacylation assay
Transport & 
Protein Import
• In vitro transport assays 
using recombinant proteins 
reconstituted into liposomes
• In organello import of 
precursor mitochondrial 
proteins 
FIGURE 2 Legend on next page.
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2.2 | Targeted gene panels
Initial application of NGS methods in mitochondrial disor-
ders tended to sequence targeted mitochondrial gene panels
that included a spectrum of genes encoding respiratory chain
components and known disease-associated genes52,53 or
more expansive panels, known as the “MitoExome,” which
included all genes listed in the MitoCarta inventory.44,45
Smaller, more focussed, gene panels have also been success-
ful in identifying variants in known genes related to a spe-
cific clinical phenotype and OXPHOS presentation. For
example, we have used a custom Ampliseq panel for genes
involved in Complex I function to identify pathogenic vari-
ants in TMEM126B and NDUFA6.43,54 The effectiveness of
this approach relies upon having biochemical evidence of an
isolated complex I defect, and with continued improvements
in turnaround times and decreasing sequencing costs of
WES, using an approach that is not restricted to a specific
subset of predetermined genes would seem sensible given
the number of possible disease genes associated with mito-
chondrial dysfunction. Indeed, at least 15 genes now associ-
ated with mitochondrial disease are not included on the
wide-ranging “MitoExome” panel55 highlighting the advan-
tages of non-targeted, unbiased approaches such as WES.
This will no doubt change again as WGS costs are already
decreasing to allow this to become more commonly used.
2.3 | Gene agnostic approaches
(WES and WGS)
In mitochondrial disease WES has been hugely successful
improving diagnostic yields in patients with nuclear gene
defects and identifying variants in novel disease genes.
Many centers now report that approximately 60% of patients
receive a genetic diagnosis.46-48 This success has led
towards a “genetics first” approach to diagnosis which may
avoid the requirement for skin or muscle biopsies entirely.
The benefits of such an approach are clear if WES or WGS
identifies a known pathogenic variant in a known disease
gene, but this is only one of many potential outcomes and
the only one that gives a firm diagnosis using sequencing
alone.
Other outcomes from WES/WGS include identifying:
(1) a novel variant in a known disease gene, (2) a novel vari-
ant in a known mitochondrial protein of known function that
has not been previously associated with disease (3) a
predicted pathogenic variant in a protein of unknown func-
tion or (4) no clear candidate variants (Figure 2). With an
ever-increasing number of variants of unknown significance
(VUS) being identified, functional validation of pathogenic-
ity is vital. Indeed, the high diagnostic rates of the aforemen-
tioned publications are partly due to WES being applied to
biochemically well-characterized cases of mitochondrial dis-
ease, which aided the prioritization of variants. For example,
in one study with more heterogeneous cohorts, the diagnos-
tic yield was less than 39% compared to 57% in the sub-
group with the highest suspicion of mitochondrial disease.48
Despite the revolutionary impact of WES on the genetic
diagnosis of mitochondrial disease, a significant proportion
of cases (~40%) remain unresolved. This may be due to the
variant being detected, but not prioritized by current bioin-
formatic pipelines or may be because the causative variant
does not reside in the coding regions of the genome. WGS
is able to detect all genetic variants and therefore has the
potential to further increase the diagnostic yield. However,
with the increased number of VUS identified and incom-
plete coverage of inherited disease genes,56 variant prioriti-
zation is a major challenge. There have been many studies
assessing the annotation of variants, with examples of pre-
viously described pathogenic variants shown to be present
in healthy individuals,57,58 calling into question the accu-
racy of disease gene annotation. Furthermore, WGS tech-
nologies are still improving and use of technical
benchmarks are required to ensure accurate interpretation
of variant calls.59
Variant prioritization is key and most in-house bioinfor-
matic filtering pipelines should take into consideration the
following: the rarity or presence of the variant in databases
such as gnomAD (http://gnomad.broadinstitute.org) or
ExAC60; conservation of the amino acid; modeling the
FIGURE 2 An overview of the workflow utilized to identify and validate variants associated with mitochondrial disease. First, clinical
information is vital to inform appropriate genetic testing. If no mitochondrial DNA (mtDNA) or syndrome-associated nuclear variants are identified,
we advocate the use of trio whole-exome (WES) or whole-genome (WGS) sequencing. For each of the outcomes of WES/WGS, different levels of
investigation are required to prove pathogenicity. Then, we have outlined some of the basic techniques that can be used to investigate the impact of
those variants on OXPHOS metabolism using patient tissue or cells. In cases where disease mechanisms are poorly understood, these materials
alongside cell and animal models can aid investigations. There is a plethora of techniques available, and instead of providing an exhaustive list we
have highlighted those most commonly used, as well as gene function-specific investigations, some of which are expanded upon in the text.
Abbreviations: Co-IP (co-immunoprecipitation); EMSA (electrophoretic mobility shift assay); FRET (fluorescence resonance energy transfer); iPSC
(induced pluripotent stem cells); MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes); MIDD (maternally inherited
diabetes and deafness); OXPHOS (oxidative phosphorylation); SBF-SEM (serial block-face scanning electron microscopy); STED (stimulated
emission depletion); TAP (transporter associated with antigen processing); TEM (transmission electron microscopy); WES (whole-exome
sequencing); WGS (whole-genome sequencing); Y2H (yeast two-hybrid)
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amino acid change in the protein (https://zhanglab.ccmb.
med.umich.edu/I-TASSER/); use of in silico tools such as
SIFT61 and PolyPhen262 to predict pathogenicity of the vari-
ant. There are online tools which can take into account these
factors such as Ensembl's Variant Effect Predictor.63 Bioin-
formatic tools will continue to improve and inclusion of such
data may allow for better assessment into the authenticity of
variants.
Guidelines from the American College of Medical Genet-
ics (ACMG) aim to standardize interpretation of variants
into five classifications (“pathogenic,” “likely pathogenic,”
“uncertain significance,” “likely benign,” and “benign”) and
there are five criteria listed as either “very strong” or
“strong” evidence for classifying novel variants as patho-
genic: (1) null variant, for example, nonsense, frameshift,
splice site etc., (2) a variant resulting in the same amino acid
change as an established pathogenic variant, (3) a de novo
variant, where paternity and maternity have been
established, (4) well-established functional studies show
damaging effect on the gene or gene product, (5) the preva-
lence of the variant in affected individuals is significantly
higher than in controls.64 There are also six criteria listed as
“moderate” and five listed as “supporting” evidence of path-
ogenicity which can be found in the ACMG standards and
guidelines.64
When using WES or WGS, we advocate the sequencing
of the family trio (ie, the patient and both unaffected par-
ents) whenever possible. Trio sequencing is particularly
powerful as it enables prioritization of de novo variants
based on knowledge of segregation within the family (listed
as criteria 3 of the ACMG guidelines above). Recently,
there have been increasing reports of de novo dominant
causes of mitochondrial disorders in cases suspected of
having a recessive etiology, including variants in
SLC25A4,65,66 ATAD3A,67 SLC25A24,68,69 DNM1L,70-72
CTBP173,74 and ISCU.75 In the case of de novo SLC25A4
variants, sequencing the family trio was vital as the clinical
phenotype of the patients did not resemble any of the previ-
ously reported patients with either autosomal dominant or
recessive variants in SLC24A4.66 Thus, the variant had
failed to be prioritized in cases where only the proband was
sequenced.
Of the five ACMG criteria we have listed above (“very
strong” or “strong”) at least two are usually required to
classify the variant as “pathogenic” rather than “likely path-
ogenic” or “unknown significance” (see ACMG standards
and guidelines for full classification rules64). Criteria
4 (functional studies) is the only one of these “strong”
criteria where there is scope to provide additional informa-
tion on the consequences of the variant that may promote
its classification to a clinically actionable level. Undertak-
ing such studies is therefore immensely valuable and
central to the genetic diagnosis of many mitochondrial
diseases.
3 | FUNCTIONAL VALIDATION
WES is currently more widely used than WGS, but we
expect this to change in the near future. There have been
calls for a first-line WGS based approach in mitochondrial
disease.76 We agree that trio WGS should form a central role
in the diagnostic process, but that the majority of cases will
likely require some degree of functional validation
(Figure 2). When a known pathogenic variant explaining the
clinical phenotype has not been identified by WES/WGS,
skin and skeletal muscle biopsies can be crucial. Their use
has enabled identification of many novel genetic associa-
tions where functional assessment was essential for affir-
ming pathogenicity. It is in this niche where skeletal muscle
biopsy continues to prove invaluable in the diagnosis of
mitochondrial disease.
3.1 | Variants in mtDNA
In the case of mtDNA variants it is helpful to assess the
mutation load if the variant is not homoplasmic, but it is
important to do so in an appropriate tissue since mutation
load can differ between tissues.13,51 Furthermore, for novel
mtDNA variants of unknown significance, the “gold stan-
dard” approach for verifying pathogenicity of a mtDNA var-
iant is to demonstrate an observable correlation between
higher mutant loads and severity of biochemical phenotype;
this is typically done, for novel mt-tRNA gene variants, by
assessing heteroplasmy in individual COX-positive and
COX-deficient fibers to demonstrate a functional
threshold.77-79
3.2 | Variants in nuclear DNA
3.2.1 | Novel variants in a known disease gene
The functional workup varies on a case by case basis, partic-
ularly when variants identified via WES are novel. When
those variants appear in a gene that has previously been
associated with disease, the functional workup requires con-
firmation of segregation in the family and demonstration of
a biochemical phenotype, where appropriate, in patient sam-
ples that is similar to the phenotype previously described in
other patients with variants in the same gene. If the clinical
and biochemical phenotypes are similar and the variant seg-
regates with disease, then there is little doubt as to the patho-
genicity of the variant.
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3.2.2 | Novel variants in a known
mitochondrial protein not associated with
disease
In cases where the results from WES have indicated a likely
pathogenic variant in a gene not previously linked to disease
then additional work may be required. If the function of the
gene is known, then it is important to design experiments to
test for an expected phenotype. For example, if the protein is
known to be involved in RNA processing then demonstrat-
ing aberrant processing and increased levels of RNA precur-
sors in patient samples can strengthen the case for the
variant being pathogenic, as was demonstrated in cell lines
harboring pathogenic TRMT10C (MRPP1) variants.80 The
gold standard for proving pathogenicity is to perform rescue
experiments by introducing a wild-type copy of the gene
into patient fibroblasts, often using a viral delivery system.
Restoration of the biochemical phenotype to control levels
upon expression of the wild-type gene allows confirmation
of pathogenicity.
3.2.3 | Novel variants in a gene encoding a
protein of unknown function
The approaches used to validate novel pathogenic variants in
genes of unknown function identified by NGS approaches
are similar to those described above with rescue experiments
being particularly important. In these cases, patient samples
can be instrumental in implicating a mitochondrial role for a
gene of unknown function (for example, RMND1,81
MGME1,82 FBXL483) or elucidating a previously unknown
mitochondrial function of a gene (for example, TRMT584
and TOP3A).85
3.2.4 | No clear candidate pathogenic variants
One aspect of functional assessment that has grown with the
advent of WGS is transcriptomics and proteomic approaches
to complement WGS data and aid in variant prioritization.
The potential of using transcriptomics (RNA sequencing
[RNA-Seq]) to tackle undiagnosed cases of mitochondrial
disease has recently been assessed.50 Of 48 cases that WES
had previously failed to diagnose, RNA-Seq yielded a
genetic diagnosis in five patients and candidate variants in
the remaining 43, including identification of novel disease
gene TIMMDC1 which encodes a complex I assembly fac-
tor.50 Additionally, Cummings and colleagues successfully
diagnosed 35% of 50 unsolved rare muscle disease cases
using RNA-Seq; this approach compared patient RNA-seq
data to RNA-seq data from 184 control skeletal muscle sam-
ples, illustrating the power required to identify significant
variations.86 They also highlighted the importance of acquir-
ing pathologically-relevant tissue; analysis of tissue from the
Genotype-Tissue Exppression (GTEx) Consortium87 rev-
ealed that many of the most common muscle-disease genes
are associated with significantly lower expression in blood
and fibroblasts compared to skeletal muscle, rendering them
underpowered. Implementation of RNA-Seq can therefore
improve diagnostic rates when utilized alongside WGS
when no clear variants are initially identified, but the tissue-
specificity of many disorders may render the use of
RNA-Seq case-limited and highlights another instance
where skeletal muscle biopsy may be essential.
4 | METHODS TO FUNCTIONALLY
VALIDATE PATHOGENICITY AND
DISSECT MOLECULAR
MECHANISMS
The techniques used to functionally characterize variants
identified by WES also varies on a case by case basis, but
there are some common approaches. Following Sanger
sequencing confirmation and demonstration that the variant
segregates with disease in the family, one of the first func-
tional tests performed is western blotting of proteins from
patient and control tissue samples. it is important to assess
the steady-state levels of the protein encoded by the variant
gene. ACMG guidelines consider frameshift variants and
those affecting splicing as loss-of-function alleles which are
defined as pathogenic with the protein expected to be absent
from affected patient tissues. Decreased steady-state protein
levels are often observed if there is a missense change, either
homozygous or compound heterozygous (with another mis-
sense or nonsense variant), indicating either lower expres-
sion levels or increased turnover of the mutant protein and
demonstrates a functional consequence of the identified vari-
ant. However, this is not always the case as variants can
cause a decrease in function without a decrease in
expression.
4.1 | Protein studies
Since our definition of mitochondrial disorders generally
focusses on impaired energy production, standard experi-
ments assess the steady-state levels of various OXPHOS
complex subunits via SDS-PAGE and immunoblotting and
assembly of each complex by blue-native PAGE. More
recent advances include complexome profiling, which uses
mass spectrometric analysis of 2D BN/SDS-PAGE before
hierarchical clustering to analyze the assembly of complexes
and their subunits. This technique can be used to assess
respiratory chain complexes43,88 and the mitoribosome,
recently showing that MRPS2-deficiency leads to aberrant
small mitoribosomal subunit formation.27 The aforemen-
tioned techniques can be achieved using either muscle
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biopsy or skin fibroblasts. Skeletal muscle often shows a
more severe molecular phenotype and can be used to further
demonstrate the pathogenic nature of variants, using oxida-
tive enzyme histochemistry and quantitative immunohisto-
chemistry89 but does not provide a renewable source of
material for further investigation into disease mechanisms,
as is the case with skin fibroblasts. For example, fibroblasts
provide an opportunity to study mitochondrial translation
defects that underlie an OXPHOS deficiency using [35S]
labeled methionine and cysteine incorporation to assess
nascent mitochondrial protein synthesis, and when
mitoribosomal defects are suspected, sucrose gradients to
analyze their assembly. These techniques recently revealed
that homozygous MRPS14 variants diminished translation,
but did not affect mitoribosomal assembly.28 An observable
biochemical defect in patient fibroblasts also allows rescue
experiments to be performed and, as stated earlier, these are
crucial for functionally confirming the pathogenicity of
novel variants in novel disease genes.
4.2 | Imaging studies
There are a multitude of imaging techniques that can help
further our understanding of the pathological role of novel
disease genes, including transmission electron microscopy
(TEM) and high-resolution confocal imaging. These tech-
niques in combination helped characterize the mitochondrial
abnormalities associated with SLC25A46 variants in Leigh
Syndrome and demonstrated the function of SLC25A46
within a mitochondrial/ER pathway involved in lipid trans-
fer.90 Similar imaging studies were employed in the charac-
terization of a mitochondrial neurodegenerative disorder
caused by NME3 variants and demonstrated that the dual
functions of NME3 (NDP-kinase activity and a role in mito-
chondrial fusion) contributed to the disease mechanism.91
High-resolution confocal microscopy in particular is playing
a major role in elucidating the roles of novel mitochondrial
genes in mitochondrial dynamics. Although many of these
genes have not yet been described in disease etiology, a bet-
ter understanding of their functions will aid prioritization of
variants in genetically undiagnosed mitochondrial disease
patients. Furthermore, the integration of improvements to
more recently developed techniques such as serial block-face
scanning electron microscopy (SBF-SEM) in skeletal muscle
will help further our understanding of mitochondrial disease
genes and disease mechanisms.92
4.3 | Modeling putative disease variants
If a biochemical defect is only detectable in skeletal muscle,
modeling experiments might be required to obtain more evi-
dence of pathogenicity. One such example is the recent
identification of de novo variants in SLC25A4 encoding the
skeletal muscle isoform of the mitochondrial ATP/ADP car-
rier.65,66 The biochemical defect was only observable in
skeletal muscle, so the equivalent mutations were modeled
in yeast and recombinant proteins were expressed in a bacte-
rial system to allow assessment of ADP/ATP transport and
demonstrate pathogenicity of the variants.
Limited availability of patient samples mean that other
model systems including cell line models (eg, CRISPR,
iPSCs) or whole organisms (eg, Drosophila, zebrafish and
mice) may be used to provide supportive evidence of patho-
genicity or to further investigate the molecular mechanisms
of disease to further the knowledge of mitochondrial
biology.
4.4 | Discovery of novel genes linked to
mitochondrial metabolism via genome wide
CRISPR/Cas9 screening
The CRISPR/Cas9 genome editing system is a powerful tool
that has accelerated our ability to discover and annotate gene
functions, particularly when patient cells harboring patho-
genic variants are not available. The phenotypic expression
and tissue-specificity of mitochondrial disorders also restrict
our understanding of disease mechanisms occurring in dif-
ferent cell types and tissues, making it difficult to dissect
exact functions of mitochondrially-destined proteins. There-
fore, generating either iPSC-based disease models93 or ani-
mal models,94,95 using genome engineering tools is
important for a complete functional characterization of mito-
chondrial disease genes.
The discovery of new genes linked to mitochondrial
metabolism through the use of functional genetic screening
approaches, including genome-wide CRISPR/Cas9 screens
can aid the interpretation of variants identified by
WES/WGS. A genome-wide CRISPR/Cas9 knockout screen
has been recently employed to identify genes essential for
human mitochondrial oxidative phosphorylation.96 The
screening strategy relied on a “death screening” using the
cell death marker Annexin V and uncovered 191 high confi-
dence genes necessary for survival in galactose rich media
where cells entirely rely on OXPHOS. In addition to the
known 72 OXPHOS disease genes, the screen also identified
two genes absent from the MitoCarta 2.0 (TMEM261 and
N6AMT1). Another high-throughput genetic screen of 2231
genes using a CRISPR interference (CRISPRi) library iden-
tified 136 mitochondrial genes involved in mitochondrial
bioenergetics.97 Additionally, the screen uncovered 20 non-
mitochondrial genes whose knockdown led to a decrease in
real-time ATP levels measured by a combined Fluorescence
Resonance Energy Transfer (FRET)-based biosensor and
Fluorescence-activated Cell Sorting (FACS) system.
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The identification of a catalogue of new genes associated
with mitochondrial metabolism will allow these to be fac-
tored into bioinformatic pipelines when analyzing
WES/WGS data and may also provide further biochemical
evidence of the mitochondrial defect, contributing to
improved patient diagnosis.
4.5 | Animal models
A variety of animal models (commonly including
Caenorhabditis elegans, Drosophila melanogaster, zebrafish
and mice) can be utilized to assess tissue specificity, disease
progression and mechanisms associated with mitochondrial
dysfunction. For example, in humans, pathogenic variants
in TRMU (encoding the mitochondrial tRNA 5-methyl-
aminomethyl-2-thiouridylate methyltransferase) are associated
with deafness-associated mitochondrial disease but the patho-
physiology was initially poorly understood.98 A CRISPR-
generated Mtu1 (homologue of human TRMU) knockout
zebrafish model offered novel insights into disease mecha-
nisms underlying the deafness seen in patients—a phenotype
that was recapitulated in the fish model.95 A recent report of
the first case of mitochondrial disease due to OXA1L variants
utilized RNA interference of the Drosophila homologue,
CG6404, to show defects in complexes I, IV, and V assembly
in flies, which was consistent with what was observed in
patient tissues.99 Despite the ease of use of zebrafish and Dro-
sophila and their ability to recapitulate mitochondrial disease
in certain cases, mice remain the most commonly developed
models for studying mitochondrial pathophysiology and dys-
function due to the genetic and physiological similarities to
humans and the potential for testing novel therapies.100 Some
mouse models recapitulate human disease effectively, for
example, mitochondrial translation optimization protein
1 (MTO1) knockout replicates the cardiomyopathy displayed
in humans.101 The mtDNA helicase Twinkle knock-in mouse
phenotype correlates strongly with human disease presenta-
tion including progressive neurodegeneration and epileptic
seizures.102 However, tissue-specific presentations are not
always recapitulated; for example, the NDUFS4 mouse model
reproduces a Leigh-like phenotype similar to that displayed
by human patients, but not the characteristic basal ganglia
changes.103,104 Furthermore, some mouse models do not dem-
onstrate corresponding biochemical phenotypes to those
observed in human patients; for example, human SURF1 vari-
ants are associated with severe mitochondrial COX defects
and early lethality whereas SURF1−/− mice demonstrate
increased longevity in the absence of many of the mitochon-
drial phenotypes associated with the human disease.105,106
The aforementioned genes are all nuclear-encoded highlight-
ing the historic difficulties associated with generating faithful
models of human disease related to pathogenic, heteroplasmic
mtDNA variants. However, using a random mutagenesis and
a phenotype-driven approach, mice with a mutation
(m.5024C > T) in the mitochondrial tRNAALA gene have been
generated,107 and more recently used to test experimental
therapeutic strategies.108,109
These studies, among many others, demonstrate animal
models can be a powerful tool to study new disease genes,
particularly when there is only a single patient or patient
samples cannot be obtained. Moving forwards, high
throughput screening using targeted CRISPR/Cas9 in
zebrafish and collaborations such as the International Mouse
Phenotyping Consortium will enable functional and
pathobiological investigations of many genes.110,111 This
will lead to the characterization of novel phenotypes and
provide candidate genes for many genetically undiagnosed
clinical diseases.
4.6 | “Multi-omic” approaches to investigate
gene functions
As discussed earlier, the identification of causal variants in
mitochondrial disease is moving slowly towards a “bi-omic”
approach that analyses the genome and transcriptome.50,86
However, truly “multi-omic” approaches are emerging in a
research setting that focus on investigating basic mitochon-
drial biology. It is easy to envisage this approach yielding
elucidations of novel disease mechanisms, especially when
new disease genes of unknown function are identified. A
recent study used analysis of mRNA, proteins, lipids and
metabolites to identify over 90 targets of the RNA-binding
protein Puf3p, and delineate its role in coordinating Coen-
zyme Q and OXPHOS biogenesis in Saccharomyces
cerevisiae.112 Previous efforts to identify Puf3p targets
delivered unclear results, as it was difficult to identify truly
productive binding events; the integration of these four
“omics” strategies highlight the power of a “multi-omics”
approach in elucidating the function of a protein in certain
situations and we expect these approaches to be used more
commonly in the future, including investigating the function
of novel mitochondrial disease genes.
5 | CONCLUDING REMARKS
The introduction of NGS into mainstream genetics, com-
bined with the large number of mitochondrial disease gene
candidates, means that putative pathogenic variants are now
identified in many different scenarios. We recognize the
many difficulties associated with assignation of pathogenic-
ity and, in our experiences, the collaborative integration of
accredited diagnostic pathways and research activity has
proven vital. Clinical information can be extremely impor-
tant in directing appropriate genetic testing, but we often
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advocate the use of WES or WGS on the basis of speed,
comprehensive coverage of nuclear and mitochondrial DNA
variants and simultaneous assessment of heteroplasmy. It
must be reiterated that in such cases it is vital that trios are
sequenced whenever possible to ensure rapid variant prioriti-
zation. Then, when novel disease genes are identified, case-
specific techniques should be undertaken to further under-
stand disease mechanisms as outlined (Figure 2). Rescue
experiments either in patient cell lines or CRISPR-generated
cell lines are particularly important in proving pathogenicity
of a novel variant.
It is also worth highlighting the importance of inter-
national collaboration within the mitochondrial disease
field. Identification of additional cases with similar clini-
cal phenotypes is hugely beneficial in being able to con-
firm pathogenicity of variants in novel disease genes.
Online tools such as GeneMatcher113 allow cases to be
brought together and aid in the collaborative effort to
report new genes associated with disease. Collaboration
has also facilitated studies that complement those in
humans, as demonstrated by the International Mouse
Phenotyping Consortium.
The main output measure in a diagnostic setting should
relate to the help offered to families affected by mitochon-
drial disease. There is no cure for mitochondrial disease so
consistent and rapid diagnosis, best delivered using NGS,
will ensure that these families are able to make informed
decisions regarding provision of care of affected members
and for many, reproductive options. It is apparent that a
“multi-omics” approach (eg, WES/WGS in addition to trans-
criptomics, proteomics, metabolomics, etc.) has the potential
to increase even further the diagnostic yield and will no
doubt result in the identification of new disease genes which
will further enhance the understanding of mitochondrial
biology and disease mechanisms.
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